Director/PDMR's Dealing

RNS Number : 7386E

Oncimmune Holdings PLC

02 March 2020

 

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Director/PDMR's Dealing

Oncimmune Holdings plc (AIM: ONC.L), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, announces the following dealing in the Company's ordinary shares of £0.01 each in the Company ("Ordinary Shares") by Carsten Schroeder, PDMR and Non-Executive Director. The Company was notified on 28 February 2020.

PDMR	Date of purchase	Number of shares purchased	Purchase price	Total shares held	% ISC held following purchase
Carsten Schroeder	28 February 2020	9,000	£0.541	9,000	0.00014%

This announcement, including the notification below, is made in accordance with the requirements of Article 19 of the EU Market Abuse Regulation.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Carsten Schroeder
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Oncimmune Holdings plc
b)	LEI	213800HCYIWT6YPI1I02
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of £0.01 each
	Identification code	ISIN: GB00BYQ94H38
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)
			Price	Volume
			0.541 GBP	9,000
d)	Aggregated information
	- Aggregated volume	Same as above
	- Price
e)	Date of the transaction	28 February 2020
f)	Place of the transaction	London stock exchange, AIM

For further information:

Oncimmune Holdings plc

Andrew Stewart, General Counsel and Company Secretary

[e-mail]  

 

END

 

 

DSHSSDFIEESSEDD